Advancing immunomodulatory functions in mesenchymal stem/stromal cells through targeting the GATA6-mediated pathway.

Eric Chang-Yi Lin, Madison P Davis, Ming-Song Lee, Gui Ma, Wei Xu, Yuan-I Chang, Wan-Ju Li

Department of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA; Institute of Physiology, College of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan.Department of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, Wisconsin, USA; Institute of Physiology, College of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taiwan. · pubmed

Paper

Abstract

The immunomodulatory capacity of mesenchymal stem/stromal cells (MSCs) is a key feature that makes them particularly valuable for regenerative medicine. However, this potential is affected by the chronological aging of the donors and the cell expansion procedures in culture. We have demonstrated that GATA binding protein 6 (GATA6) plays a pivotal role in the aging of MSCs and inhibiting GATA6 rejuvenates the characteristics of MSCs.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper addresses the aging of mesenchymal stem/stromal cells (MSCs) and explores a pathway (GATA6) that influences their immunomodulatory functions. This is relevant to longevity research as it investigates a mechanism that could potentially rejuvenate MSCs, which are important for regenerative medicine and may have implications for age-related decline. However, while the findings are solid, they appear to be an incremental advance rather than a groundbreaking discovery, limiting their overall impact.

Author of this paper? Send a correction.